Stay updated on Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.

Latest updates to the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference3%

- Check15 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. No other page content appears affected.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.2%

- Check36 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.2%

- Check43 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new medical terms related to treatment techniques. Notably, the drug pembrolizumab has been reintroduced, indicating a focus on specific therapeutic options.SummaryDifference2%

- Check58 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.